Candida News and Research

RSS

How an opportunistic fungal pathogen knows when to attack

The opportunistic fungal pathogen Candida albicans inconspicuously lives in our bodies until it senses that we are weak, when it quickly adapts to go on the offensive. The fungus, known for causing yeast and other minor infections, also causes a sometimes-fatal infection known as candidemia in immunocompromised patients. An in vivo study, published in mBio, demonstrates how C. albicans can distinguish between a healthy and an unhealthy host and alter its physiology to attack.

25 Jul 2012

Sosei completes SO-1105 Phase I trial for oropharyngeal candidiasis in Japan

Sosei Group Corporation, the biopharmaceutical company, today announces that its wholly owned Japanese subsidiary, Sosei Co., Ltd., has successfully completed a Japanese Phase I trial for SO-1105 for the treatment of oropharyngeal candidiasis.

2 Jul 2012

NovaDigm reports positive data from Phase 1 NDV-3 vaccine program

NovaDigm Therapeutics, a company developing innovative vaccines for fungal and bacterial infections, today announced the presentation of positive data for its NDV-3 vaccine program in a second Phase 1 study.

7 May 2012

New diagnostic test for Trichomonas vaginalis

Medical Diagnostic Laboratories, L.L.C. is a CLIA certified infectious disease laboratory which specializes in high-complexity, state-of-the-art, automated DNA-based molecular analyses.

2 Apr 2012

Abbott receives CE Marking for PLEX-ID instrument and assays

Abbott announced today it has obtained CE Marking (Conformite Europeene) in the European Union to market its rapid, high-throughput PLEX-ID instrument, along with three assays for use on the system: PLEX-ID Viral IC Spectrum, PLEX-ID BAC Spectrum BC and PLEX-ID Flu.

31 Mar 2012

Deletion of Hms1 protein inhibits Candida albicans infection

Scientists at the University of Toronto have found a molecular mechanism that plays a key role in the transition of Candida albicans yeast into disease-causing fungus-one of the leading causes of hospital-acquired infection.

17 Mar 2012

Sosei initiates SO-1105 Phase I trial in oropharyngeal candidiasis

Sosei Group Corporation, the biopharmaceutical company, today announces that its wholly owned Japanese subsidiary, Sosei Co., Ltd., has initiated a Japanese Phase I trial for SO-1105 for the treatment of oropharyngeal candidiasis.

8 Mar 2012

Candida albicans can sense immune status of host cells and evade them

Glen Palmer, PhD, Assistant Professor of Microbiology, Immunology & Parasitology at LSU Health Sciences Center New Orleans, was part of an international research team led by Luigina Romani, MD, at the University of Perugia, that discovered opportunistic fungi like Candida albicans can sense the immune status of host cells and adapt, evading immune system defenses.

23 Feb 2012

Ivera receives new FDA clearance for Curos disinfecting port protector

Ivera Medical Corporation today announced it has received a new FDA 510(k) clearance for its Curos disinfecting port protector which reflects the company's ongoing determination to continuously improve its products to better deliver solutions designed to reduce hospital-acquired catheter related bloodstream infections.

18 Jan 2012

Pevion announces further data from clinical study of PEV7 therapeutic Candida vaccine

Pevion Biotech AG today announced further data from the ongoing clinical study of its therapeutic Candida vaccine PEV7, demonstrating the generation of specific and functional B cell memory in 100% of vaccinees. Furthermore, the results again confirm the capability of Pevion's second generation virosomal vaccine platform to induce strong and long-lasting immunity in humans against otherwise weak antigens .

17 Jan 2012

Woman's ovarian cycle plays an important role in her susceptibility to infection

A new research report in the Journal of Leukocyte Biology suggests that a woman's ovarian cycle plays an important role in her susceptibility to infection.

4 Jan 2012

Effective ways to reduce risk of vaginal yeast infection

Vaginal thrush is one of the most popular topics on NHS Choices website. This common yeast infection affects around 75% (three-quarters) of women at some point. Up to half of these will have thrush more than once.

21 Oct 2011

Pfizer releases Phase III study results comparing VFEND-ERAXIS combination to VFEND for IA

Pfizer Inc. today reported the top-line results of an international Phase III clinical trial which compared the combination of VFEND (voriconazole) and ERAXISTM (anidulafungin) to VFEND monotherapy for primary therapy of invasive aspergillosis, a life-threatening invasive fungal infection that can develop as a complication in patients with compromised immune systems.

1 Oct 2011

Positive data from NovaDigm's NDV-3 vaccine preclinical study on VVC

NovaDigm Therapeutics, a company developing innovative vaccines for fungal and bacterial infections, today announced the presentation of positive data from a preclinical study evaluating the efficacy its NDV-3 vaccine in a model of vulvovaginal candidiasis (VVC), which is primarily caused by Candida albicans.

20 Sep 2011

Positive Phase 1 data for NovaDigm NDV-3 vaccine presented at 51st ICAAC

NovaDigm Therapeutics, a company developing innovative vaccines for fungal and bacterial infections, today announced the presentation of positive Phase 1 data for its NDV-3 vaccine program at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC).

19 Sep 2011

Positive data from NovaDigm's NDV-3 vaccine program to be presented at ICAAC conference

NovaDigm Therapeutics, a company developing innovative vaccines for fungal and bacterial infections, today announced that the Company will present positive data for its NDV-3 vaccine program at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), taking place September 17-20, 2011 in Chicago, IL.

13 Sep 2011

Researchers discover how yeast cells identify, attach to human tissue and cause infection

Researchers are a step closer towards creating a new class of medicines and vaccines to combat drug-resistant and deadly strains of fungal infections, following a new study published today in Proceedings of the National Academy of Sciences.

6 Sep 2011

Temple University, URMC partner to translate novel medical research into new drugs

The University of Rochester Medical Center (URMC) and Temple University School of Pharmacy have announced a partnership that will help translate novel medical research into new drugs for treating diseases.

19 Aug 2011

Novel link between two receptors mediates fungal recognition in macrophages

Whitehead Institute researchers have uncovered a novel association between two fungal recognition receptors on the surface of certain immune cells, called macrophages.

9 Aug 2011

Scientists discover protein involved in nerve cell motor-cargo mechanism

With every bodily movement-from the blink of an eye to running a marathon-nerve cells transmit signals to muscle cells. To do that, nerve cells rely on tiny molecular motors to transport chemical messengers that excite muscles cells into action. It's a complex process, which scientists are still trying to understand. A new study by Syracuse University researchers has uncovered an important piece of the puzzle.

26 May 2011